🟢 Alzamend Neuro is trading 6.92% up in pre-market as catalyst remains unclear

Alzamend Neuro is trading at $1.70, up 6.92% in pre-market, with no identified company-specific announcement explaining the September 1, 2026 rise.

• Latest company releases concern clinical-presentation acceptances and financing activity.
• The move comes despite weaker U.S. futures: Nasdaq futures are down 0.83% amid higher yields, oil prices, and Middle East tensions.
• Because the stock is rising against the broader market, the catalyst remains unclear.